^
Association details:
Biomarker:BRAF V600E
Cancer:Neurofibrosarcoma
Drug:Zelboraf (vemurafenib) (BRAF inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor

Excerpt:
A patient with sporadic metastatic MPNST and the BRAF V600E mutation was treated with standard doses of sorafenib and later vemurafenib and followed for response. The patient showed a rapid but modest and transient response to sorafenib and a very dramatic response to vemurafenib. This case represents the first report of successful systemic treatment of MPNST with an inhibitor of the BRAF V600E mutation.
DOI:
10.6004/jnccn.2013.0173